Skip to Content

Amprenavir Pregnancy and Breastfeeding Warnings

Amprenavir is also known as: Agenerase

Amprenavir Pregnancy Warnings

An Antiretroviral Pregnancy Registry has been to monitor maternal-fetal outcome of amprenavir exposures during pregnancy. To register patients, physicians should call 1-800-258-4263 (USA).

Amprenavir has been assigned to pregnancy category C by the FDA. High-dose animal studies have revealed evidence of an increased incidence of abortions, skeletal variations due to incomplete ossification of bones, thymic elongation, and reduced body weights. There are no controlled data in human pregnancy. Amprenavir should only be given during pregnancy when benefit outweighs risk. The oral solution of amprenavir is contraindicated during pregnancy due to the potential risk of toxicity to the fetus from the high propylene glycol content.

See references

Amprenavir Breastfeeding Warnings

There are no data on the excretion of amprenavir into human milk. It is excreted into rat milk. HIV-infected mothers should not breast-feed their infants due to the risk of transmission of HIV via breast milk.

See references

References for pregnancy information

  1. Perinatal HIV Guidelines Working Group "Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. Available from: URL: http://aidsinfo.nih.gov/c" ([2008 Jul 8]):
  2. "Product Information. Agenerase (amprenavir)." Glaxo Wellcome, Research Triangle Pk, NC.
  3. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents -- A Working Group of the Office of AIDS Research Advisory Council (OARAC) "Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available from: URL: http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf." ([2006 Oct 10]):

References for breastfeeding information

  1. "Product Information. Agenerase (amprenavir)." Glaxo Wellcome, Research Triangle Pk, NC.
  2. Perinatal HIV Guidelines Working Group "Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. Available from: URL: http://aidsinfo.nih.gov/c" ([2008 Jul 8]):

See Also...

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and Drugs.com is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide